

MedLife assesses the opportunity to attract funding through the Bucharest Stock Exchange (BVB) in amount of approx. €80 million to reinforce the healthcare service market

Approximately €20 million may be attracted by increasing the share capital, and approximately €60 million by issuing bonds. The funds thus attracted will be intended for the purchasing programme and for greenfield projects

Bucharest, 10 August 2017: MedLife's Board of Directors convened the General Shareholders' Meeting for 13 September 2017, in view of approving several items on the agenda.

MedLife's BD proposes to the GSM its delegation and authorisation, until 13 September 2020, to take decisions regarding the increase of MedLife's share capital, by the maximum amount of Lei 650,000.

This increase will take place by issuing maximum 2.6 million new shares, in exchange for cash contributions, and if this increase is made at the maximum authorised level, the share capital will go from Lei 5,023,000 to Lei 5,673,000.

At the same time, MedLife's BD proposes to the GSM to approve the issuance of non-guaranteed corporate bonds, with a total nominal value of maximum Lei 274,200,000, which shall be given to investors through a private investment or a public offer. This issuance of bonds will be made, according to the market conditions and the company's funding needs, in a single issuance or in an offer programme.

"In recent years, MedLife has preserved its position of clear leader of the healthcare service market, by completing 16 successful acquisitions and integrations, besides its solid organic growth. We wish to take advantage of the opportunities provided by the market, and as we estimate that next year we will complete a few significant transactions, we are preparing to take over the central role in reinforcing the market. We are very lucky to have made successful acquisitions, to have brought a considerable value to all minority shareholders in our subsidiaries after their integration in the group. We believe that the way we have kept our promises recommends us as a trustworthy partner and buyer and we wish to take full advantage of this unique position and to bring new significant entities and partners to our group", said Mihai Marcu, MedLife President and CEO.

The MedLife shares started being traded on the capital market in Bucharest on 21 December 2016 for a price of Lei 26 per unit. The total value of the initial public offer was Lei 230 million for a package of 44% of the company's shares, namely 8,840,480 shares, with 8,036,800 being basic shares, to which an additional number of 803,680 over-allocated shares was added. MedLife is part of the BET and BET-TR index structure, as one of the companies with the most liquid shares.

About MedLife:

MedLife is the largest private healthcare provider in Romania. The company operates the widest network of clinics, one of the large networks of medical laboratories, general and specialised hospitals and it has the largest client database for Healthcare Prevention Packages in the country. In addition, from the

Please contact us for any additional details:

Alis Lupu
PR Specialist
Mobile: 0746 46 46 34
E-mail: alupu@medlife.ro
<http://www.medlife.ro>

standpoint of sales, it is one of the largest private healthcare companies in Central and Eastern Europe, according to the public information available to MedLife Group.

The shares issued by MedLife SA are traded on the spot regulated market managed by the Bucharest Stock Exchange, Premium Category, with the "M" trading symbol.

MedLife Group has a successful history as regards both organic growth and growth by acquisitions. As of 2009, it has opened or acquired over 83 medical units. Its strong and experienced management team has been capable of creating and managing these growth opportunities, acquiring valuable knowledge and experience, which can allow finding the best way to continue expanding successfully.

Contact details:

Dorin Preda

Tel: +40 746 46 46 06

E-mail: dpreda@medlife.ro

Legal disclaimer

This press release is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of Med Life SA's securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy Med Life SA's securities. Neither this presentation nor anything in it shall form the basis of any contract or commitment. This press release is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any investor.

All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate. Med Life SA has prepared this press release based on information available to it, including information derived from public sources that have not been independently verified. This report may contain forward-looking statements. These statements reflect Med Life SA's current knowledge and its expectations and projections about future events and may be identified by the context of such statements or words such as "anticipate," "believe", "estimate", "expect", "intend", "plan", "project", "target", "may", "will", "would", "could" or "should" or similar terminology. These financial projections are preliminary and subject to change; Med Life SA undertakes no obligation to update or revise these forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events.

Inevitably, some assumptions may not materialize, and unanticipated events and circumstances may affect the ultimate financial results. Projections are inherently subject to substantial and numerous uncertainties and to a wide variety of significant business, economic and competitive risks. Therefore, the final results achieved may vary significantly from the forecasts, and the variations may be material.